PMC:7386875 / 1618-2455
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T9 | 69-76 | Body_part | denotes | heparin | http://purl.org/sig/ont/fma/fma82839 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T26 | 27-35 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T27 | 47-57 | Disease | denotes | thrombosis | http://purl.obolibrary.org/obo/MONDO_0000831 |
| T28 | 306-314 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T29 | 722-730 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T30 | 754-778 | Disease | denotes | coronavirus disease 2019 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T31 | 780-788 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T3 | 69-76 | Chemical | denotes | heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
| T4 | 83-93 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
| T5 | 108-113 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T6 | 115-125 | Chemical | denotes | nafamostat | http://purl.obolibrary.org/obo/CHEBI_135466 |
| T7 | 131-143 | Chemical | denotes | dipyridamole | http://purl.obolibrary.org/obo/CHEBI_4653 |
| T8 | 205-214 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T9 | 459-464 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T11 | 224-530 | Sentence | denotes | The growing awareness and mechanistic understanding of the prothrombotic state of COVID-19 patients are driving efforts to more stringent diagnostic screening for thrombotic complications and to the early institution of antithrombotic drugs, for both the prevention and therapy of thrombotic complications. |
| T12 | 531-731 | Sentence | denotes | The shifting paradigm of diagnostic and treatment strategies holds significant promise to reduce the burden of thrombotic complications and ultimately improve the prognosis for patients with COVID-19. |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 55 | 315-323 | Species | denotes | patients | Tax:9606 |
| 56 | 708-716 | Species | denotes | patients | Tax:9606 |
| 57 | 69-76 | Chemical | denotes | heparin | MESH:D006493 |
| 58 | 115-125 | Chemical | denotes | nafamostat | MESH:C032855 |
| 59 | 131-143 | Chemical | denotes | dipyridamole | MESH:D004176 |
| 85 | 27-35 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 86 | 47-57 | Disease | denotes | thrombosis | MESH:D013927 |
| 87 | 306-314 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 88 | 387-411 | Disease | denotes | thrombotic complications | MESH:D013927 |
| 89 | 505-529 | Disease | denotes | thrombotic complications | MESH:D013927 |
| 90 | 642-666 | Disease | denotes | thrombotic complications | MESH:D013927 |
| 91 | 722-730 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 134 | 754-778 | Disease | denotes | coronavirus disease 2019 | MESH:C000657245 |
| 135 | 780-788 | Disease | denotes | COVID-19 | MESH:C000657245 |